Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 1252-1258, March 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lozonschi, L.
Right arrow Articles by Matsuno, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lozonschi, L.
Right arrow Articles by Matsuno, S.
[Cancer Research 59, 1252-1258, March 15, 1999]
© 1999 American Association for Cancer Research


Experimental Therapeutics

Controlling Tumor Angiogenesis and Metastasis of C26 Murine Colon Adenocarcinoma by a New Matrix Metalloproteinase Inhibitor, KB-R7785, in Two Tumor Models1

Lucian Lozonschi, Makoto Sunamura2, Masao Kobari, Shinichi Egawa, Lianghao Ding and Seiki Matsuno

First Department of Surgery, Tohoku University School of Medicine, Sendai 980-8574, Japan

ABSTRACT

Experimental evidence has directly implicated matrix metalloproteinases (MMPs) in the remodeling of the stromal tissue surrounding tumors. Thus, MMP inhibitors could limit the expansion of both neoplastic cell compartment and endothelial cell compartment of a tumor. Much of the work on the role of MMP inhibitors has concentrated on their inhibitory effects on tumor cell invasion. We have examined the effects of a new MMP inhibitor, KB-R7785 (acting on MMP-1, MMP-3, and MMP-9), on tumor angiogenesis and metastasis of murine colon adenocarcinoma (C-26) in two tumor models in BALB/c mice (transparent chamber model and lung colonization model). KB-R7785 has not shown inhibitory effects on in vitro growth of either C-26 or KOP2.16 murine endothelial cells. In vivo, KB-R7785 administrated twice daily for 15 days (100 mg/kg, i.p.), starting the day of tumor inoculation (5 x 105 C26 cells) in transparent chamber, has resulted in 88.2% suppression of tumor growth, compared with that in vehicle-administered mice (controls). Tumors grown in controls have doubled their area in 3.3 days, whereas those treated by KB-R7785 progressed almost four times slower (tumor area doubling time, 12 days). KB-R7785 rendered centrally avascular tumors with only a rim of peripheral neovasculature, which had significant lower functional vascular density and vascular area than the corresponding parameters in control tumors 10 days after inoculation [79.9 ± 6.7 cm/cm2versus 164.1 ± 10.1 cm/cm2 (P < 0.01) and 19.8 ± 1.5% versus 42.6 ± 2.7% (P < 0.01), respectively]. In the lung colonization model (tail vein inoculation of 5 x 105 C-26 cells), administration of KB-R7785 (100 mg/kg, i.p.) twice daily for 20 days has reduced the number of surface metastasis by 85.8% and abolished the tumor burden, as compared with controls. The few metastatic colonies found in the lungs of KB-R7785 treated mice appeared to be dormant (i.e., staining with von Willebrand factor antibody revealed few, if any, positive cells within the metastatic foci from MMP inhibitor-treated lungs, whereas terminal deoxynucleotidyl transferase-mediated nick end labeling showed a 4-fold increase in the rate of tumor cell apoptosis compared with controls. The fact that KB-R7785 interferes with early steps of angiogenesis and cancer spread suggests that MMP inhibitors may control both primary and secondary tumor growths by limiting the expansion of endothelial cells, as well as cancer cells, composing the tumors.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
R. A. Dean, G. S. Butler, Y. Hamma-Kourbali, J. Delbe, D. R. Brigstock, J. Courty, and C. M. Overall
Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis
Mol. Cell. Biol., December 15, 2007; 27(24): 8454 - 8465.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Luo, Y.-J. Wen, Z.-Y. Ding, C.-H. Fu, Y. Wu, J.-Y. Liu, Q. Li, Q.-M. He, X. Zhao, Y. Jiang, et al.
Immunotherapy of tumors with protein vaccine based on chicken homologous tie-2.
Clin. Cancer Res., March 15, 2006; 12(6): 1813 - 1819.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. S. Lakka, C. S. Gondi, D. H. Dinh, W. C. Olivero, M. Gujrati, V. H. Rao, C. Sioka, and J. S. Rao
Specific Interference of Urokinase-type Plasminogen Activator Receptor and Matrix Metalloproteinase-9 Gene Expression Induced by Double-stranded RNA Results in Decreased Invasion, Tumor Growth, and Angiogenesis in Gliomas
J. Biol. Chem., June 10, 2005; 280(23): 21882 - 21892.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T.-W. CHUNG, S.-K. MOON, Y.-C. CHANG, J.-H. KO, Y.-C. LEE, G. CHO, S.-H. KIM, J.-G. KIM, and C.-H. KIM
Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism
FASEB J, November 1, 2004; 18(14): 1670 - 1681.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dona, I. Dell'Aica, E. Pezzato, L. Sartor, F. Calabrese, M. D. Barbera, A. Donella-Deana, G. Appendino, A. Borsarini, R. Caniato, et al.
Hyperforin Inhibits Cancer Invasion and Metastasis
Cancer Res., September 1, 2004; 64(17): 6225 - 6232.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Ichikawa, T. Miura, A. Nakano, T. Miki, Y. Nakamura, K. Tsuchihashi, and K. Shimamoto
The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioning
Cardiovasc Res, April 1, 2004; 62(1): 167 - 175.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
K. D. Burman
A New Paradigm in the Treatment of Carcinoma: Specific Molecular Targeting
Endocrinology, March 1, 2004; 145(3): 1027 - 1030.
[Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. E. Turner, A. L. Harris, S. Melmed, and J. A. H. Wass
Angiogenesis in Endocrine Tumors
Endocr. Rev., October 1, 2003; 24(5): 600 - 632.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.-y. Liu, Y.-q. Wei, L. Yang, X. Zhao, L. Tian, J.-m. Hou, T. Niu, F. Liu, Y. Jiang, B. Hu, et al.
Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2
Blood, September 1, 2003; 102(5): 1815 - 1823.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S. Hague, I.Z. MacKenzie, R. Bicknell, and M.C.P. Rees
In-vivo angiogenesis and progestogens
Hum. Reprod., March 1, 2002; 17(3): 786 - 793.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. G. Naglich, M. Jure-Kunkel, E. Gupta, J. Fargnoli, A. J. Henderson, A. C. Lewin, R. Talbott, A. Baxter, J. Bird, R. Savopoulos, et al.
Inhibition of Angiogenesis and Metastasis in Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291
Cancer Res., December 1, 2001; 61(23): 8480 - 8485.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Pepper
Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis
Arterioscler. Thromb. Vasc. Biol., July 1, 2001; 21(7): 1104 - 1117.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Seandel, K. Noack-Kunnmann, D. Zhu, R. T. Aimes, and J. P. Quigley
Growth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen
Blood, April 15, 2001; 97(8): 2323 - 2332.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Hidalgo and S. G. Eckhardt
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
H. E. Turner, Zs. Nagy, M. M. Esiri, A. L. Harris, and J. A. H. Wass
Role of Matrix Metalloproteinase 9 in Pituitary Tumor Behavior
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2931 - 2935.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
M. Haq, A. Shafii, E. E. Zervos, and A. S. Rosemurgy
Addition of Matrix Metalloproteinase Inhibition to Conventional Cytotoxic Therapy Reduces Tumor Implantation and Prolongs Survival in a Murine Model of Human Pancreatic Cancer
Cancer Res., June 1, 2000; 60(12): 3207 - 3211.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
PNAS, April 11, 2000; 97(8): 3884 - 3889.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. G. Duda, M. Sunamura, L. Lozonschi, T. Kodama, S.-i. Egawa, G. Matsumoto, H. Shimamura, K. Shibuya, K. Takeda, and S. Matsuno
Direct in Vitro Evidence and in Vivo Analysis of the Antiangiogenesis Effects of Interleukin 12
Cancer Res., February 1, 2000; 60(4): 1111 - 1116.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.